ClinicalTrials.gg
CompletedNCT01387542PRESENTUpdated Mar 5, 2013Results posted

Safety and Efficacy Study of Paliperidone Extended Release (ER) Among Thai Schizophrenia Participants

A Phase 4 interventional study of Paliperidone extended release (ER) in Schizophrenia, sponsored by Janssen-Cilag Ltd.,Thailand. Completed at 2 sites in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-03-05.

Sponsored by Janssen-Cilag Ltd.,Thailand (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.

Enrollment
95th of 115
40 · median 178
Started
2009
with 10 others
Phase 4
42 of 115
5 open now
Registered
65th of 115
by date

Among the 115 studies testing paliperidone in Schizophrenia, this one is the 95th largest by enrollment, is one of 11 that started in 2009, is one of 42 in phase 4, and was the 65th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About paliperidone

paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies testing paliperidone in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effectiveness and safety of paliperidone extended release (ER) treatment in Thai schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) participants.

Read the detailed description

This is an open-label (all people know the identity of the intervention), non-randomized (the study drug is not assigned by chance) study to evaluate the efficacy and safety of paliperidone ER in adult Thai schizophrenia participants. The study consists of a screening phase and an open-label treatment phase. Study duration will be 10 weeks and participants can either be inpatient or outpatient. The recommended paliperidone ER starting and maintenance dose will be 6 milligram (mg) per day for most participants. Throughout the study, flexible dosing ranging from 3 to 12 mg per day may be used at the discretion of the investigator. Throughout the study, participants will be evaluated for efficacy using clinician rating (Clinical and Global Impressions-Severity [CGI-S] scale, and Personal and Social Performance Scale [PSP]) scales. Safety of the participants will be monitored.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • Paliperidone Extended Release (ER)
  • INVEGA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet the (DSM-IV) criteria for schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self)
  • Participants unsatisfied with their previous treatment
  • Previously or currently on oral atypical antipsychotics

Exclusion criteria

Exclusion Criteria:

  • Serious unstable medical condition, including recent and present laboratory abnormalities
  • History or current symptoms of tardive dyskinesia (twitching or jerking movements that you cannot control in your face, tongue, or other parts of your body)
  • History of neuroleptic malignant syndrome (high fever, rigid muscles, shaking, confusion, sweating more than usual, increased heart rate or blood pressure, or muscle pain or weakness)
  • Pregnant or breast-feeding female
  • Participation in an drug trial within 30 days prior to selection
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Paliperidone Extended Release (ER)

    Paliperidone ER 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral tablets depending on investigator's discretion once daily for 10 weeks

    Drug: Paliperidone extended release (ER)

Interventions

  • Paliperidone ER 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral tablets depending on investigator's discretion once daily for 10 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Clinical Global Impression Severity (CGI-S) Scale at Week 10

    The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants". Higher scores indicate worsening .

    Time frame: Baseline, Week 10

  2. Change From Baseline in Personal and Social Performance (PSP) Total Score at Week 2

    The PSP scale assesses degree of a participant's dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. Score ranges from 1 to 100, divided into 10 equal intervals to rate degree of difficulty (1, absent to 6, very severe) in each of the 4 domains. Based on 4 domains there will be 1 total score. Participants with score of 71 to 100 have mild degree of difficulty; from 31 to 70, varying degrees of disability; less than or equal to 30, functioning so poorly as to require intensive supervision.

    Time frame: Baseline, Week 2

  3. Change From Baseline in Personal and Social Performance (PSP) Total Score at Week 6

    The PSP scale assesses degree of a participant's dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. Score ranges from 1 to 100, divided into 10 equal intervals to rate degree of difficulty (1, absent to 6, very severe) in each of the 4 domains. Based on 4 domains there will be 1 total score. Participants with score of 71 to 100 have mild degree of difficulty; from 31 to 70, varying degrees of disability; less than or equal to 30, functioning so poorly as to require intensive supervision.

    Time frame: Baseline, Week 6

  4. Change From Baseline in Personal and Social Performance (PSP) Total Score at Week 10

    The PSP scale assesses degree of a participant's dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. Score ranges from 1 to 100, divided into 10 equal intervals to rate degree of difficulty (1, absent to 6, very severe) in each of the 4 domains. Based on 4 domains there will be 1 total score. Participants with score of 71 to 100 have mild degree of difficulty; from 31 to 70, varying degrees of disability; less than or equal to 30, functioning so poorly as to require intensive supervision.

    Time frame: Baseline, Week 10

07

Results

Posted Mar 5, 2013
Limitations and caveats
Study had an open-label trial design with lack of a comparator arm; therefore it was difficult to conclude the efficacy and safety results.

Participant flow

Participant flow — Overall Study
MilestonePaliperidone Extended Release (ER)
Started40
Treated38
Completed32
Not completed8
Withdrew: Adverse event3
Withdrew: Withdrawal by subject1
Withdrew: Changed diagnosis1
Withdrew: Insufficient response1
Withdrew: Non-compliant1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryChange From Baseline in Clinical Global Impression Severity (CGI-S) Scale at Week 10

The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants". Higher scores indicate worsening .

Time frame:
Baseline, Week 10
Reported as:
Mean · Units on a scale
Change From Baseline in Clinical Global Impression Severity (CGI-S) Scale at Week 10
Units on a scalePaliperidone Extended Release (ER)
Baseline3.55 ± 1.155
Change at Week 100.82 ± 1.036
Statistical analysis
  • Paliperidone Extended Release (ER) · Friedman test · p = 0.000
PrimaryChange From Baseline in Personal and Social Performance (PSP) Total Score at Week 2

The PSP scale assesses degree of a participant's dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. Score ranges from 1 to 100, divided into 10 equal intervals to rate degree of difficulty (1, absent to 6, very severe) in each of the 4 domains. Based on 4 domains there will be 1 total score. Participants with score of 71 to 100 have mild degree of difficulty; from 31 to 70, varying degrees of disability; less than or equal to 30, functioning so poorly as to require intensive supervision.

Time frame:
Baseline, Week 2
Reported as:
Mean · Units on a scale
Change From Baseline in Personal and Social Performance (PSP) Total Score at Week 2
Units on a scalePaliperidone Extended Release (ER)
Baseline58.95 ± 15.710
Change at Week 2-4.289 ± 9.647
Statistical analysis
  • Paliperidone Extended Release (ER) · Paired t-test · p = 0.009
PrimaryChange From Baseline in Personal and Social Performance (PSP) Total Score at Week 6

The PSP scale assesses degree of a participant's dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. Score ranges from 1 to 100, divided into 10 equal intervals to rate degree of difficulty (1, absent to 6, very severe) in each of the 4 domains. Based on 4 domains there will be 1 total score. Participants with score of 71 to 100 have mild degree of difficulty; from 31 to 70, varying degrees of disability; less than or equal to 30, functioning so poorly as to require intensive supervision.

Time frame:
Baseline, Week 6
Reported as:
Mean · Units on a scale
Change From Baseline in Personal and Social Performance (PSP) Total Score at Week 6
Units on a scalePaliperidone Extended Release (ER)
Change From Baseline in Personal and Social Performance (PSP) Total Score at Week 6-7.053 ± 11.463
Statistical analysis
  • Paliperidone Extended Release (ER) · Paired t-test · p = 0.001
PrimaryChange From Baseline in Personal and Social Performance (PSP) Total Score at Week 10

The PSP scale assesses degree of a participant's dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. Score ranges from 1 to 100, divided into 10 equal intervals to rate degree of difficulty (1, absent to 6, very severe) in each of the 4 domains. Based on 4 domains there will be 1 total score. Participants with score of 71 to 100 have mild degree of difficulty; from 31 to 70, varying degrees of disability; less than or equal to 30, functioning so poorly as to require intensive supervision.

Time frame:
Baseline, Week 10
Reported as:
Mean · Units on a scale
Change From Baseline in Personal and Social Performance (PSP) Total Score at Week 10
Units on a scalePaliperidone Extended Release (ER)
Change From Baseline in Personal and Social Performance (PSP) Total Score at Week 10-9.868 ± 14.640
Statistical analysis
  • Paliperidone Extended Release (ER) · Paired t-test · p = 0.000

Adverse events

Collected over 10 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paliperidone Extended Release (ER)—1/40 (2.5%)22/40 (55%)
Most frequent serious events
Most frequent serious events
EventPaliperidone Extended Release (ER)
ManiaPsychiatric disorders1/40
Elevated moodPsychiatric disorders1/40
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPaliperidone Extended Release (ER)
DrowsinessNervous system disorders6/40
HeadacheNervous system disorders6/40
InsomniaPsychiatric disorders5/40
Extrapyramidal disorderNervous system disorders3/40
NauseaGastrointestinal disorders3/40
ConstipationGastrointestinal disorders2/40
DiarrheaGastrointestinal disorders2/40
HypotensionVascular disorders2/40
PruritisSkin and subcutaneous tissue disorders2/40
PalpitationCardiac disorders2/40

Baseline characteristics

Age Continuous
Age Continuous(Years)Paliperidone Extended Release (ER)
Mean41.13 ± 12.314
Sex: Female, Male
Sex: Female, Male(Participants)Paliperidone Extended Release (ER)
Female23
Male15
08

Study locations

2 sites
  • Chiang Mai, Thailand
  • Songkhla, Thailand
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2009, a primary completion of Sep 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2013, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2011
First posted
Jul 4, 2011
Start
Aug 2009
Primary completionActual
Sep 2010
CompletionActual
Sep 2010
Results first posted
Mar 5, 2013
Last update
Mar 5, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01387542
Responsible party
Sponsor
First posted
Jul 4, 2011
Start date
Aug 2009
Primary completion
Sep 2010
Completion
Sep 2010
Results posted
Mar 5, 2013
Last update
Mar 5, 2013

Study contacts

Janssen-Cilag Ltd.,Thailand Clinical Trial
study director · Janssen-Cilag Ltd.,Thailand

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paliperidone

Start the discussion